The International Aspirin Foundation 2017: ASPIRIN: 120 Years of Innovation attracted worldwide speakers.
Sign up to be part of the aspirin community and be the first to receive latest information.
Have something to say about aspirin?
Menu
Our biennial conference is a great opportunity to hear from leading biomedical researchers across a range of specialties. By coming together discuss the latest international data, we can enhance understanding, build stronger networks and inspire new ideas.
The International Aspirin Foundation 2017: ASPIRIN: 120 Years of Innovation attracted worldwide speakers.
Action Research Professor of Neurology, Director of the Stroke Prevention Research Unit, University of Oxford
Peter Rothwell is the Action Research Professor of Neurology in the Nuffield Department of Clinical Neuroscience, University of Oxford. He qualified in medicine at the University of Edinburgh in 1987 and after completing his early postgraduate clinical training he moved to Oxford as Clinical Lecturer in Neurology in 1996. He was awarded an MRC Senior Clinical Fellowship in 1999 and set up the Stroke Prevention Research Unit in 2000, which now employs over 40 research staff.
He was awarded Professor of Clinical Neurology in 2004 and was elected a fellow of the Academy of Medical Sciences in 2008, a National Institute of Health Research Senior Investigator in 2009 and a Wellcome Trust Senior Investigator in 2011. He has published over 400 scientific papers and several books. His research interests include primary and secondary prevention of stroke, the effects of blood pressure on the brain, and the risks and benefits of aspirin.
He is clinically active, working as a Consultant Neurologist for the Oxford University Hospitals Trust and contributing to clinical services for general neurology and stroke prevention. He has received several awards for other areas of his research, including the Inaugural British Medical Journal Award for Outstanding Contribution to Clinical Research (2009), the Foulkes Foundation Medal, Academy of Medical Sciences (2009), the World Stroke Organisation President’s Biennial Award for Outstanding Research (2010), a Wellcome Trust Senior Investigator Award (2011), the Kinmonth Medal, Royal College of Surgeons (2012), the Queen’s Anniversary Prize for Higher and Further Education (2013) and The Inaugural International Aspirin Foundation Senior Scientific Award (2014).
Dong Zhao, chief physician, PhD, doctoral tutor, deputy director of Beijing Institute of heart lung and blood vessel disease, director of epidemiology research department, An Zhen Hospital, Beijing, China
Experts Committee member for: Disease Control of the Ministry of Health, National Cardiovascular Center, Chinese Society of Cardiology, Cardiovascular Disease branch of Chinese Physicians’ Association, International Society of Atherosclerosis.
Vice chairman for: Chinese Society for prevention of chronic diseases, Cardiovascular Disease Branch of Chinese Female Physicians’ Association.
Involved in Chinese Guidelines and international guidelines update: Prevention and Treatment of Hypertension, Prevention and Treatment of Dyslipidemia, Guideline for Cardiovascular Disease Prevention. World Health Organization Guidelines for cardiovascular disease prevention and American Heart Association guidelines of Cardiovascular Disease Prevention in women. Published more than 200 hundreds papers in professional journals.
Award: the first prize of Scientific Progress Award of the Ministry of Education in 2011, the Chinese Medical Prize in 2013, the second prize of Scientific and Technological Progress in Beijing City in 2005.
Professor Sir John Burn obtained an MD with distinction, a first class honours degree in human genetics from Newcastle University, where he has been Professor of Clinical Genetics since 1991 and a consultant specialist since 1984. He led the regional NHS Genetics Service for 20 years and helped to create the Centre for Life which houses an education and science centre alongside the Institute of Genetic Medicine and Northgene Ltd, the identity testing company he launched in 1995. He chairs DNA device company QuantuMDx. He was knighted in 2010, chosen as one of the first 20 ‘local heroes’ to have a brass plaque on Newcastle Quayside in 2014. He received the Living North award in 2015 for services to the North East 2000 – 2015. He is also a non-Executive Director of NHS England.
Dr Andrew T Chan is an Associate Professor of Medicine at Harvard Medical School and an attending gastroenterologist at Massachusetts General Hospital (MGH) with a clinical specialty in familial gastrointestinal cancer syndromes. He is Chief of the Clinical and Translational Epidemiology Unit and the Program Director for gastroenterology training at MGH. His research focus is in clinical and translational epidemiology of colorectal cancer, with a focus on chemoprevention with aspirin.
Christopher Hawkey is Professor of Gastroenterology at the Nottingham Digestive Diseases Centre. His main interests are in the field of non-steroid anti-inflammatory drugs and inflammatory bowel disease. In both areas his approach is to try to identify targets in small exploratory studies and then evaluate them in large and/or outcomes studies.
Dr John WK Chia is Senior Consultant, at the National Cancer Centre Singapore. Graduating from the National University of Singapore, he later obtained his Membership of the Royal College of Physicians in Edinburgh in 2002 and upon completing his Oncology Boards, he underwent fellowship training in “Immunotherapy for Solid Tumors” – with Malcom Brenner at the Centre for Cell and Gene Therapy, Baylor College, Houston, for the development of cancer vaccines and adoptive T-cell therapy. He undertook a second clinical fellowship in with Prof Stan Kaye at The Royal Marsden Hospital London from 2011 to 2012 in the advanced management of Gynecological cancers.
Dr Chia is active in clinical trial research; and has developed and/or led numerous clinical trial studies– including immune check-point inhibitors, cancer vaccines, adoptive T cell therapy, and small molecule targets for cancer and he holds scientific research grants both locally and internationally.
Dr Ruth Langley is based at the UK Medical Research Council Clinical Trials Unit at University College London where she jointly leads the Cancer Group; and has a clinical consultant post at the Brighton and Sussex University Hospital.
She has a particular interest in gastro-oesophageal malignancy and has co-ordinated a series of trials and associated translational studies, and has led the investigation of the use of transdermal oestrogen in the treatment of prostate cancer.
Dr Langley is the Chief Investigator of an international trial (Add-Aspirin) designed to assess the effect of aspirin as an additional adjuvant agent in several common solid tumours.
Sign up to be part of the aspirin community and be the first to receive latest information.
Have something to say about aspirin?
Have something to say about aspirin?
Please fill in the form below and we will contact you with further information.
Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.
Medical Oncology
In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.
I received grant support for investigator-initiated research from:
I hold shares in: Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics
I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.
Junbo Ge
Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.
Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.
AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award
Click here to find the press release.
I received consultant Bayer and Pfizer, Inc.
I received grant support for investigator-initiated research from:
Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
Discipline: Cardiology and Epidemiology
I received consultant and speaker fees Bayer.
I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.
Pierre Amarenco, MD, FAHA, FAAN
Neurology and Vascular Neurology
N/A
I received consultant and speakers fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon.
I received grant support for investigator-initiated research from:
Have something to say about aspirin?
We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.